CVS Weighs Spinning Off Retail Pharmacy Unit, Decision Could Come With Q3 Results
CVS sits 35% above its 52-week low of $69.51 on elevated volume (2.4× avg).
Summary
CVS is discussing a spin-off of its retail pharmacy division, a break-up of a business empire the FT values at $117 billion, with the breakup set to occur in the first half of 2028. The move could be announced as early as this week's third-quarter results, which makes it live rather than theoretical. Splitting off the stores would leave the company concentrated in Aetna insurance and the Caremark pharmacy benefits business, two segments that already drive most of the earnings. The retail arm has been the drag: it carries the front-of-store traffic problem and the legal overhang, including the $315 million opioid settlement CVS Pharmacy agreed to in October. A separation would let the market value the insurance and PBM assets on their own, which is the core of the bull case here. Watch the Q3 release this week for confirmation and terms.
At the time of this announcement, CVS was trading at $94.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $116.9B. The 52-week trading range was $69.51 to $110.68. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.